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Dronedarone is a new antiarrhythmic drug with an amiodarone-
like benzofuran structure. Shortly after its introduction, dronedar-
one became implicated in causing severe liver injury. Amiodarone 
is a well-known mitochondrial toxicant. The aim of our study was 
to investigate mechanisms of hepatotoxicity of dronedarone in 
vitro and to compare them with amiodarone. We used isolated rat 
liver mitochondria, primary human hepatocytes, and the human 
hepatoma cell line HepG2, which were exposed acutely or up to 
24 h. After exposure of primary hepatocytes or HepG2 cells for 
24 h, dronedarone and amiodarone caused cytotoxicity and apopto-
sis starting at 20 and 50µM, respectively. The cellular ATP content 
started to decrease at 20µM for both drugs, suggesting mitochon-
drial toxicity. Inhibition of the respiratory chain required concen-
trations of ~10µM and was caused by an impairment of complexes 
I and II for both drugs. In parallel, mitochondrial accumulation 
of reactive oxygen species (ROS) was observed. In isolated rat 
liver mitochondria, acute treatment with dronedarone decreased 
the mitochondrial membrane potential, inhibited complex I, and 
uncoupled the respiratory chain. Furthermore, in acutely treated 
rat liver mitochondria and in HepG2 cells exposed for 24 h, drone-
darone started to inhibit mitochondrial β-oxidation at 10µM and 
amiodarone at 20µM. Similar to amiodarone, dronedarone is 
an uncoupler and an inhibitor of the mitochondrial respiratory 
chain and of β-oxidation both acutely and after exposure for 24 h. 
Inhibition of mitochondrial function leads to accumulation of ROS 
and fatty acids, eventually leading to apoptosis and/or necrosis 
of hepatocytes. Mitochondrial toxicity may be an explanation for 
hepatotoxicity of dronedarone in vivo.
Key Words:  benzofuran derivatives; mitochondria; uncoupling; 
electron transport chain; apoptosis.
Amiodarone is a well-established antiarrhythmic drug 
(Julian et  al., 1997; Morse et  al., 1988), which is associated 
with several potentially severe adverse reactions (Mason, 1987; 
Stelfox et al., 2004). Importantly, it is a hepatic mitochondrial 
toxicant (Lewis et al., 1989, 1990; Morse et al., 1988), which 
has been described to uncouple oxidative phosphorylation, to 
inhibit enzyme complexes of the electron transport chain and to 
impair fatty acid β-oxidation (Fromenty et al., 1990; Fromenty 
and Pessayre, 1995; Kaufmann et  al., 2005; Spaniol et  al., 
2001; Waldhauser et al., 2006). Mitochondrial β-oxidation and 
oxidative phosphorylation are fundamental physiological pro-
cesses as evidenced by inherited impairment of these pathways, 
which can affect the function of many organs, including the 
liver (Krahenbuhl et al., 1999). Patients treated with amiodar-
one for several months or years may thus suffer from micro- 
and/or macrovesicular steatosis, a disease that may progress to 
steatohepatitis and may eventually be fatal (Lewis et al., 1990; 
Simon et al., 1984).
Dronedarone, a structural analog of amiodarone, was specifi-
cally designed to minimize the adverse reactions associated 
with amiodarone (Dobrev and Nattel, 2010). As shown in 
Figure 1, dronedarone is a noniodinated amiodarone derivative 
carrying a methylsulfonamide group at the benzofurane ring that 
decreases its lipophilicity. Similar to amiodarone, dronedarone 
is metabolized by N-desalkylation of the basic side chain by 
cytochrome P450 (CYP) 3A4 (Patel et  al., 2009). Although 
the N-desalkylated metabolites are toxic for amiodarone 
(Waldhauser et al., 2006; Zahno et al., 2011), this is currently 
not known for dronedarone.
Shortly after its introduction, severe hepatic injury has been 
reported in two patients treated with dronedarone, eventually 
leading to liver transplantation (Anonymous, 2011). Recently, 
Serviddio et al. (2011) published a study in which they investi-
gated liver mitochondrial toxicity of dronedarone and amiodar-
one in vivo in rats. Similar to previous studies (Fromenty et al., 
1990; Kaufmann et al., 2005; Spaniol et al., 2001), amiodar-
one inhibited the activity of complex I of the respiratory chain, 
uncoupled oxidative phosphorylation, and was associated with 
increased reactive oxygen species (ROS) production and lipid 
peroxidation. In contrast, dronedarone only uncoupled oxida-
tive phosphorylation, but was not associated with inhibition of 
the respiratory chain or increased ROS production.
In this study, we aimed to investigate and to better understand 
the mechanisms of cytotoxicity of dronedarone in vitro using 
isolated rat liver mitochondria, primary human hepatocytes, 
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and HepG2 cells, a well-characterized human hepatoma cell 
line (Zahno et al., 2011). We compared the toxic effects associ-
ated with dronedarone with those of amiodarone. Because the 
two drugs are structurally related (Fig. 1) and both can cause 
hepatic injury, we hypothesized that their mechanism of toxic-
ity may be similar. The systems used allowed to study the toxic-
ity acutely and after different exposure periods as well as after 
cytochrome P450 (CYP) induction.
MATERIALS AND METHODS
Chemicals. Dronedarone hydrochloride was extracted from commercially 
available tablets (brand name Multaq) from ReseaChem life science GmbH 
(Burgdorf, Switzerland). The manufacturer declared the substance 99% pure by 
high-performance liquid chromatography and confirmed the structure by 1H-
NMR analysis. Amiodarone hydrochloride was purchased from Sigma-Aldrich 
(Buchs, Switzerland). Stock solutions were prepared in dimethylsulfoxide 
(DMSO) and stored at −20°C. All other chemicals used were purchased from 
Sigma-Aldrich or Fluka, except where indicated.
Cell lines and cell culture. The human hepatoma cell line HepG2 was pro-
vided by ATCC (Manassas, VA) and maintained in Dulbecco’s Modified Eagle 
Medium (DMEM, with 1.0 g/l glucose, 4mM l-glutamine, and 1mM pyruvate) 
from Invitrogen (Basel, Switzerland). The culture medium was supplemented 
with 10% (vol/vol) heat-inactivated fetal calf serum, 2mM GlutaMax, 10mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffer and nones-
sential amino acids. Cell culture supplements were all purchased from GIBCO 
(Paisley, UK). Cells were kept at 37°C in a humidified 5% CO
2
 cell culture incu-
bator and were passaged using trypsin. The cell number was determined using a 
Neubauer hemacytometer and viability using the trypan blue exclusion method.
Cryopreserved primary human hepatocytes were purchased from Becton 
Dickinson (BD Gentest, Woburn, MA). They were recovered and cultured 
according to the protocol of the manufacturer. Induction of CYP3A4 was 
achieved by preincubation of recovered primary human hepatocytes with 20µM 
rifampicin for 72 h (Zahno et al., 2011).
Rat liver mitochondria. Male Sprague Dawley rats were kept in the ani-
mal facility of the University Hospital Basel (Basel, Switzerland) in a temper-
ature-controlled environment with a 12-h light/dark cycle and food and water 
ad libitum. Animal procedures were conducted in accordance with the insti-
tutional guidelines for the care and use of laboratory animals. The mean rat 
weight was 433 ± 79 g and the mean liver weight 12 ± 4 g. Rats were sacrificed 
by pentobarbital overdose (100 mg/rat), and liver mitochondria were isolated 
by differential centrifugation according to the method of Hoppel et al. (1979). 
The mitochondrial protein content was determined using the bicinchoninic acid 
(BCA) protein assay kit from Merck (Darmstadt, Germany).
Cytotoxicity. Cytotoxicity was determined using ToxiLight BioAssay 
Kit (Lonza, Basel, Switzerland) according to the manufacturer’s manual. 
This assay measures the release of adenylate kinase, a marker for loss of 
cell membrane integrity, using a firefly luciferase system. After drug incuba-
tion, 100 µl assay buffer was added to 20µl supernatant from drug-treated 
cell culture medium, and luminescence was measured after incubation in the 
dark for 5 min, using a Tecan M200 Pro Infinity plate reader (Männedorf, 
Switzerland).
Intracellular ATP content. Intracellular ATP was determined using 
CellTiterGlo Luminescent cell viability assay (Lonza), in accordance with the 
manufacturer’s manual. In brief, 100 µl assay buffer was added to each 96-well 
containing 100 µl culture medium. After incubation in the dark for 30 min, 
luminescence was measured using a Tecan M200 Pro Infinity plate reader.
Annexin V and propidium iodide staining. Apoptosis and necrosis were 
investigated using annexin V and propidium iodide (PI) staining (Invitrogen). 
Cells were treated with the test compounds for 24 h and stained with 1  µl 
annexin V-Alexa Fluor 647 and 1 µl propidium iodide 100 µg/ml in 100 µl 
annexin V binding buffer (10mM HEPES, 140mM NaCl, 2.5mM CaCl
2
 in 
H
2
O, pH 7.4). Cells were incubated for 15 min at room temperature (RT) and 
analyzed by flow cytometry using a CyAn ADP cytometer (Beckman Coulter, 
Marseille, France). Data were analyzed using FlowJo 9.3.2 software (Tree Star, 
Ashland, OR).
Caspase 3/7 assay. Caspase 3/7 activity was determined using the lumi-
nescent Caspase-Glo 3/7 Assay (Promega, Wallisellen, Switzerland). The assay 
was conducted according to the manufacturer’s protocol.
Cytochrome c release. Quantitative determination of cytochrome c was 
performed as described by Waterhouse and Trapani (2003). HepG2 cells 
(100,000) were harvested and permeabilized with digitonin (10  µg/ml in 
Dulbecco’s PBS [DPBS] without calcium) at RT for 20 min. Cells were fixed 
in paraformaldehyde (4% in DPBS) for 20 min at RT and were washed with 
blocking buffer (bovine serum albumin [BSA] 10% in DPBS) for 1 h and incu-
bated over night at 4°C with 1:1000 purified mouse anti-cytochrome c mono-
clonal antibody (BD Pharmingen, Basel, Switzerland) in blocking buffer. Cells 
were washed with blocking buffer and incubated for 1 h with 1:1000 Alexa 
Fluor 488-labeled secondary antibody (Alexa Fluor 488 goat anti-mouse IgG, 
Invitrogen). After an additional washing step with DPBS, the cell suspensions 
were examined by flow cytometry. Because the selective permeabilization of 
the plasma membrane allows cytoplasmic cytochrome c to diffuse out of the 
FIG. 1. Chemical structures of dronedarone and amiodarone.
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cell, mitochondrial release of cytochrome c into the cytoplasm leads to a low 
cellular cytochrome c content.
Cellular oxygen consumption using the Seahorse XF24 analyzer.  
Cellular respiration was measured using a Seahorse XF24 analyzer (Seahorse 
Biosciences, North Billerica, MA). HepG2 cells were seeded in Seahorse XF 
24-well culture plates at 20,000 cells/well in DMEM growth medium and 
allowed to adhere overnight. Cells were treated with the drugs for 24 h. Before 
the experiment, the medium was replaced with 750  µl unbuffered medium 
using an XF Prep Station (Seahorse Biosciences), and cells were equilibrated 
for 40 min at 37°C in a CO
2
-free incubator. Basal oxygen consumption was 
determined in the presence of glutamate/pyruvate (4 and 1mM, respectively). 
After inhibition of mitochondrial phosphorylation by adding oligomycin (1µM) 
to determine the oxidative leak, the mitochondrial electron transport chain 
was stimulated maximally by the addition of the uncoupler carbonyl cyanide 
p-(trifluoromethoxyl)-phenyl-hydrozone (FCCP, 1µM). Finally, the extramito-
chondrial respiration was determined after the addition of the complex I inhibi-
tor rotenone (1µM). For the determination of the basal respiration, the oxidative 
leak, and maximal respiration, extramitochondrial respiration was subtracted.
Respiration by permeabilized HepG2 cells and isolated mitochondria.  
The activity of specific enzyme complexes of the respiratory chain was analyzed 
using an Oxygraph-2k high-resolution respirometer equipped with DatLab 
software (Oroboros Instruments, Innsbruck, Austria). Freshly isolated rat liver 
mitochondria or HepG2 cells were suspended in MiR06 (mitochondrial respi-
ration medium containing 0.5mM EGTA, 3mM MgCl
2
, 60mM K-lactobionate, 
20mM taurine, 10mM KH
2
PO
4
, 20mM HEPES, 110mM sucrose, 1 g/l fatty 
acid-free BSA, and 280 U/ml catalase, pH 7.1) and transferred to the precali-
brated oxygraph chambers.
Activities of complexes I  and II were assessed in isolated rat liver mito-
chondria using l-glutamate/malate (10 and 2mM, respectively) as substrates, 
followed by the addition of ADP (2.5mM) and succinate/rotenone (10mM and 
0.5µM, respectively). The oxidative leak, a measure for uncoupling, was deter-
mined by assessing the residual oxygen consumption after addition of oligomy-
cin (1µM). Uncoupling was achieved by the addition of FCCP (1µM).
The activities of complexes I, II, III, and IV were assessed in HepG2 cells 
permeabilized with digitonin (10 µg/1 million cells). In a first run, complexes 
I and III were analyzed using l-glutamate/malate as substrate followed by the 
addition of ADP and the inhibitor rotenone. Afterwards, duroquinol (500µM, 
Tokyo Chemical Industry, Tokyo, Japan) was added to investigate complex III 
and inhibited with antimycin A (2.5µM). In a second run, complexes II and IV 
were analyzed using succinate/rotenone as substrate, followed by the addition 
of ADP and the inhibitor antimycin A. Afterwards N,N,N´,N´-tetramethyl-p-
phenylenediamine/ascorbate (0.5 and 2mM, respectively) was added to investi-
gate complex IV and inhibited with KCN (1mM).
We confirmed the integrity of the outer mitochondrial membrane by show-
ing the absence of a stimulatory effect of exogenous cytochrome c (10µM) on 
respiration. Respiration was expressed as oxygen consumption per mg protein. 
Protein concentrations were determined using the Pierce BCA protein assay 
kit from Merck.
Mitochondrial membrane potential. The mitochondrial membrane 
potential was determined as described by Kaufmann et al. (2005) with some 
modifications. Freshly isolated rat liver mitochondria were washed with incu-
bation buffer containing 137mM sodium chloride, 4.74mM potassium chloride, 
2.56mM calcium chloride, 1.18mM potassium phosphate, 1.18mM magnesium 
chloride, 10mM HEPES, and 1 g/l glucose (pH 7.4). Then, mitochondria were 
incubated at 37°C in incubation buffer containing 0.5 µl/ml [phenyl-3H]-tet-
raphenylphosphonium bromide (40 Ci/mmol, Anawa trading SA, Wangen, 
Switzerland). After 15 min, the suspension was centrifuged and the mitochon-
drial pellet resuspended in fresh nonradioactive incubation buffer. Afterwards, 
mitochondria were treated with test substances for 1 h at 37°C and centrifuged. 
After the incubation, radioactivity of the mitochondrial pellet was measured on 
a Packard 1900 TR liquid scintillation analyzer.
Mitochondrial accumulation of reactive oxygen species. HepG2 cells 
were stained with Hoechst 33342 trihydrochloride trihydrate (final concentra-
tion 20 µg/ml DMEM, Invitrogen) for 30 min at 37°C, followed by the addition 
of and MitoSOX red (final concentration 5µM in DMEM, Invitrogen) and 
dronedarone (5, 10, and 20µM) or amiodarone (10, 20, and 50µM). Real-time 
accumulation of superoxide was analyzed over 6 h using a Cellomics ArrayScan 
VTI HCS Reader (Thermo scientific, Pittsburg, PA).
mRNA expression of superoxide dismutase 1 and superoxide dismutase 2.  
The mRNA expression of superoxide dismutase 1 (SOD1) and superoxide 
dismutase 2 (SOD2) was assessed using real-time PCR as described previ-
ously (Mullen et al., 2011). HepG2 cells were treated for 24 h, and RNA was 
extracted and purified using the Qiagen RNeasy mini extraction kit (Qiagen, 
Hombrechtikon, Switzerland). The purity and quantity of RNA were evalu-
ated with the NanoDrop 2000 (Thermo Scientific, Wohlen, Switzerland), 
and cDNA was synthesized from 10  µg RNA using the Qiagen omniscript 
system. The real-time PCR was performed in triplicate using SYBR Green 
(Roche Diagnostics, Rotkreuz, Basel). We used primers specific for the 
cytosolic SOD1 (forward: 5´-TGGCCGATGTGTCTATTGAA-3´, reverse: 
5´-ACCTTTGCCCAAGTCATCTG-3´) and mitochondrial SOD2 (forward: 
5´-GGTTGTTCACGTAGGCCG-3´, reverse: 5´-CAGCAGGCAGCTGGCT-3´) 
and calculated relative quantities of specifically amplified cDNA with the 
comparative-threshold cycle method. GAPDH was used as endogenous 
reference (forward: 5′-CATGGCCTTCCGTGTTCCTA-3′; reverse: 5′-CCT-
GCTTC ACCACCTTCTTGA-3′) and no-template and no-reverse-transcription 
controls were used to exclude nonspecific amplification (Mullen et al., 2011).
Mitochondrial β-oxidation. Metabolism of [1-14C] palmitic acid (60 mCi/
mmol; PerkinElmer, Schwerzenbach, Switzerland) was assessed via the forma-
tion of 14C-acid–soluble β-oxidation products. Experiments were performed as 
previously described (Kaufmann et al., 2005) with some modifications. Isolated 
rat liver mitochondria were incubated for 15 min in the presence of the test com-
pounds in assay buffer (200µM Na-palmitate, 0.1 pCi/ml [1-14C] palmitic acid 
(60 mCi/mmol), 70mM sucrose, 43mM KCl, 3.6mM MgCl
2
, 7.2mM KH
2
PO
4
, 
36mM Tris, 2mM ATP, 500µM l-carnitine, 150µM coenzyme A, 50mM acetoac-
etate, 170µM BSA essentially fatty acid free, pH 7.4) at 37°C in a thermomixer 
at 600 rpm (Eppendorf, Switzerland). HepG2 cells were permeabilized with digi-
tonin (10 µg/million cells) after drug exposure for 24 h and incubated for 1 h in 
the same assay buffer. The reactions were stopped by adding 400 µl 20% perchlo-
ric acid, and samples were precipitated for 20 min on ice before centrifugation 
(10,000 × g, 2 min). Radioactivity was measured in the supernatant.
Intracellular lipid accumulation. Experiments were performed as 
described by Donato et al. (2009). HepG2 cells were exposed for 24 h to exoge-
nous lipids (DMEM containing 62µM of a 2:1 mixture of oleate and palmitate). 
Cells were treated with toxicants in lipid-free medium for 24 h, and intracellular 
lipid accumulation was measured using BODIPY 493/503 (final concentration 
3.75 ng/ml), a nonpolar derivative of the BODIPY fluorophore (Donato et al., 
2009). Cell suspensions were stained for 30 min at 37°C in Hank’s buffered salt 
solution buffer in the dark, before examining by flow cytometry without any 
additional washing step. In order to exclude nonviable cells, PI was added and 
the analysis was restricted to live-cell populations.
Statistical methods. Data are given as the mean ± SEM of at least three 
independent experiments. Statistical analyses were performed using GraphPad 
Prism 5 (GraphPad Software, La Jolla, CA). One-way ANOVA was used for 
comparisons of more than two groups, followed by the comparisons between 
incubations containing toxicants and the control group using Dunnett’s posttest 
procedure. Differences between induction experiments were compared using 
two-way ANOVA followed by Bonferroni’s post hoc test. P-values < 0.05 (*) 
or < 0.01 (**) were considered significant.
RESULTS
Cytotoxicity in Primary Human Hepatocytes and 
HepG2 Cells
In primary human hepatocytes, dronedarone caused adenylate 
kinase release starting at a concentration of 20µM after treatment 
for 6 or 24 h, whereas amiodarone was not toxic up to 100µM 
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(Fig.  2A). In HepG2 cells, dronedarone and amiodarone were 
both toxic starting at 50 and 100µM, respectively (Fig.  2B). 
Intracellular ATP started to decrease at 20µM for both dronedar-
one and amiodarone after exposure for 6 or 24 h, suggesting that 
mitochondria were affected before cytotoxicity could be dem-
onstrated (Fig. 2C). CYP3A4 induction by rifampicin increased 
the cytotoxicity of both 100µM amiodarone (42%) and 20µM 
dronedarone (21%). Considering the only small increase in drone-
darone-associated cytotoxicity with CYP3A4 induction, the fol-
lowing studies were carried out with the parent compounds only.
Acute Effects on Isolated Rat Liver Mitochondria
Reduced cellular ATP content was compatible with impaired 
mitochondrial function, which has been reported previously 
for amiodarone (Fromenty et  al., 1990; Spaniol et  al., 2001; 
Waldhauser et  al., 2006). As shown in Figure 3A, both ami-
odarone and dronedarone reduced the membrane potential of 
isolated rat liver mitochondria, confirming this assumption. 
Both toxicants impaired concentration dependently the max-
imal function of the electron transport chain in the presence 
of oligomycin and FCCP and acted as uncouplers of oxida-
tive phosphorylation as evidenced by an increase of the res-
piratory leak in the presence of oligomycin (Figs. 3B and 3C). 
Further investigation of oxidative phosphorylation revealed a 
concentration-dependent decrease of state 3 respiration in the 
presence of l-glutamate/malate by both toxicants (Figs. 4A and 
4B). With succinate as substrate, the inhibition was less pro-
nounced, showing only for amiodarone a significant inhibition 
of state 3 respiration at 50µM (Figs. 4A and 4B).
Subacute Mitochondrial Toxicity in HepG2 Cells
The oxygen consumption of intact HepG2 cells was assessed 
at drug concentrations that were not cytotoxic in previous 
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FIG. 2. Cytotoxicity and effect on intracellular ATP content. Cytotoxicity was assessed using the Toxi-Light assay. (A) Cytotoxicity in primary human 
hepatocytes after drug exposure for 6 or 24 h. (B) Cytotoxicity in HepG2 cells after drug exposure for 6 or 24 h. (C) Intracellular ATP content in HepG2 cells 
expressed as a percentage of the values obtained for DMSO (control). (D) Effect of pretreatment with rifampicin on cytotoxicity. Primary human hepatocytes 
were pretreated with rifampicin and then exposed to dronedarone or amiodarone for 24 h. CYP induction by rifampicin was associated with a 21% increase in 
cytotoxicity for dronedarone and a 42% increase for amiodarone. If not indicated otherwise, cytotoxicity data are expressed as percent increase compared with 
DMSO control. Drone: dronedarone, Amio: amiodarone. Data represent the mean ± SEM of at least three independent experiments. *p < 0.05 versus DMSO 
control. **p < 0.01 versus DMSO control.
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FIG.  3. Effect on membrane potential and oxidative metabolism of freshly isolated rat liver mitochondria. (A) Mitochondria were labeled with 
[3H]-tetraphenylphosphonium bromide, and mitochondrial accumulation of radioactivity was determined. DMSO served as control and was set at 100%. (B) and 
(C) Acute effect of dronedarone and amiodarone on the respiratory leak (respiration in the presence of oligomycin) and maximal (FCCP-induced) respiration 
after acute drug exposure. Drone: dronedarone, Amio: amiodarone, Oligo: oligomycin. Data represent the mean ± SEM of at least three individual preparations. 
*p < 0.05 versus control. **p < 0.01 versus control.
DM
SO
 
0.1
 
%
Dr
on
e 
5 µ
M
Dr
on
e 
10
 
µM
Dr
on
e 
20
 
µM
 
Dr
on
e 
50
 
µM
0
500
1000
1500
2000
2500
Glut/ mal (state 2)
ADP (state 3)
Succ/ rot (state 3)
** **
**
O 2
 
flu
x 
(pm
o
l x
 s
-
1 x
 m
g 
pr
o
te
in
-
1 )
DM
SO
 
0.1
 
%
Am
io 5
 
µM
Am
io 
10
 
µM
Am
io 
20
 
µM
 
Am
io 
50
 
µM
0
500
1000
1500
2000
2500
Glut/ mal (state 2)
ADP (state 3)
Succ/ rot (state 3)
**
**
**
*
O 2
 
flu
x 
(pm
o
l x
 s
-
1 x
 m
g 
pr
o
te
in
-
1 )
A B
FIG. 4. Acute effect of dronedarone and amiodarone on oxidative metabolism of freshly isolated rat liver mitochondria. Glut/mal: glutamate/malate, Succ/rot: 
succinate/rotenone, Drone: dronedarone, Amio: amiodarone. Data represent the mean ± SEM. *p < 0.05 versus control. **p < 0.01 versus control.
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experiments. Figures 5A and 5B show oxygen consumption 
of HepG2 cells after treatment with vehicle (DMSO), drone-
darone (5µM, 10µM), or amiodarone (5µM, 10µM) for 24 h. 
A  concentration of 5µM did not significantly decrease basal 
and maximal respiration for both drugs, whereas the higher 
concentration decreased maximal (uncoupled) respiration for 
both drugs significantly (Fig. 5C). The respiratory leak after the 
addition of oligomycin was not significantly increased by the 
toxicants (Fig. 5C), suggesting that dronedarone and amiodar-
one had no uncoupling effect in HepG2 cells exposed for 24 h 
at these low concentrations.
In order to investigate the mechanism of decreased maximal 
respiration, the respiratory capacities through the complexes of 
the electron transport chain were analyzed using high-resolu-
tion respirometry. After exposure to 10µM dronedarone or ami-
odarone for 24 h, the respiratory capacities through complexes 
I and II were decreased for both drugs (Fig. 5D).
As expected from toxicants inhibiting complex I  (Drose 
and Brandt, 2012), mitochondrial superoxide accumulated in 
HepG2 cells when exposed to the toxicants (Figs. 6A and 6B). 
At the same time, mRNA expression of mitochondrial SOD2 
was increased, whereas the expression of the cytoplasmic 
SOD1 remained unchanged (Fig. 6C), underscoring that drone-
darone and amiodarone mainly affect mitochondria.
Effect on Mitochondrial β-Oxidation and Cellular 
Accumulation of Fatty Acids
Mitochondrial β-oxidation was monitored by the formation 
of acid-soluble β-oxidation products from palmitate in isolated 
rat liver mitochondria after acute exposure to dronedarone 
and amiodarone. Dronedarone started to inhibit β-oxidation 
by isolated rat liver mitochondria at 20µM and amiodarone 
at 100µM (Fig. 7A). In permeabilized HepG2 cells after 24 h 
drug exposure, dronedarone started to inhibit mitochondrial 
β-oxidation at 10µM and amiodarone at 20µM (Fig. 7B). As a 
consequence, intracellular lipid accumulation was significant 
after exposure to 20µM dronedarone or 50µM amiodarone for 
24 h.
Mechanisms of Cell Death in HepG2 Cells
In order to investigate the mechanism of cell death, exter-
nalization of phosphatidylserine was analyzed using annexin 
V and disintegration of cell membranes with PI. Flow cytomet-
ric analysis of HepG2 cells revealed a progressive increase of 
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FIG. 5. Subacute effect of dronedarone and amiodarone on oxidative metabolism of HepG2 cells. (A) and (B) Oxygen consumption rate after 24 h exposure 
for dronedarone or amiodarone measured on the Seahorse XF24 analyzer. (C) Basal respiration, oxidative leak, and maximal respiration after 24 h drug exposure 
measured on the Seahorse XF24 analyzer. (D) Respiratory capacity through complexes I, II, III, and IV after 24 h drug exposure measured on the Oxygraph-2k 
high-resolution respirometer. Drone: dronedarone, Amio: amiodarone, Oligo: oligomycin. Data present the mean ± SEM. *p < 0.05, **p < 0.01 versus control.
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early and late apoptotic cells with increasing concentrations of 
dronedarone or amiodarone (Fig. 8A). The activity of caspases 
3/7, key mediators of apoptosis, was increased after treatment 
with 20µM dronedarone for 6 or 24 h, and after treatment with 
50µM amiodarone for 24 h (Fig. 8B). Furthermore, the release 
of cytochrome c from mitochondria was significant after 6 or 
24 h of incubation with 5µM dronedarone and with 20µM or 
5µM amiodarone, respectively (Fig. 8C). Mitochondrial release 
of cytochrome c is a marker of permeabilization of the mito-
chondrial outer membrane, activating the intrinsic apoptotic 
pathway (Antico Arciuch et al., 2012).
DIScUSSION
Our investigations demonstrate that both dronedarone and 
amiodarone are uncouplers and inhibitors of the mitochondrial 
respiratory chain and also inhibit mitochondrial β-oxidation. 
Furthermore, exposure to dronedarone and amiodarone was 
associated with cellular superoxide accumulation and lipid 
storage, eventually leading to apoptosis and/or necrosis.
Both compounds tested were toxic for isolated liver 
mitochondria, primary human hepatocytes, and HepG2 cells. 
They impaired mitochondrial function starting at concentrations 
between 10 and 20µM, whereas cytotoxicity was observed 
at higher concentrations, namely 20µM for dronedarone and 
50µM for amiodarone. At therapeutic dosages, amiodarone 
reaches plasma concentrations in the range of ~2µM (Lafuente-
Lafuente et  al., 2009). In liver, amiodarone concentrations 
are 10–20 times higher than in plasma (Wyss et  al., 1990), 
suggesting that the results of this study are clinically relevant. 
This assumption is supported by the observation that in 104 
patients treated with amiodarone and followed prospectively, 
25 developed an increase in serum transaminases and 3 out of 
these 25 patients symptomatic liver injury (Lewis et al., 1989). 
For dronedarone, plasma concentrations reached at therapeutic 
dosages are in the range of 0.2µM (Patel et al., 2009), which is 
~50 times lower than the lowest concentration where we started 
to observe mitochondrial toxicity. Dronedarone is almost 
completely absorbed and its bioavailability is only 15% (Hoy 
and Keam, 2009), suggesting that the hepatic concentrations 
may be higher than in plasma. This may even more so in patients 
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FIG. 6. Mitochondrial ROS production and SOD expression by HepG2 cells. (A) and (B) Mitochondrial ROS accumulation in the presence of dronedarone 
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amiodarone. Data present the mean ± SEM. *p < 0.05, **p < 0.01 versus control.
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with low hepatic CYP3A4 activity, in particular in patients 
treated concomitantly with CYP3A4 inhibitors, because 
dronedarone is metabolized mainly by CYP3A4 (Dorian, 2010; 
Patel et al., 2009). Although dronedarone was at least as toxic as 
amiodarone in this study, slightly less patients appear to develop 
liver injury during treatment with dronedarone compared with 
amiodarone. In large clinical studies, between 0.6 and 13.6% 
of the patients treated with dronedarone have been reported to 
develop liver injury (Connolly et al., 2011; Hohnloser et al., 
2009; Singh et al., 2007). The large variation can be explained 
by different definitions of liver injury and by the patients 
included into the studies. No patient in these studies developed 
symptomatic liver injury. The apparently lower hepatic toxicity 
of dronedarone compared with amiodarone in clinical studies 
may at least partially be explained by the assumption that the 
tissue accumulation of dronedarone is less accentuated than for 
amiodarone due to the lower lipophilicity of dronedarone (Hoy 
and Keam, 2009). As a consequence, as discussed above, only 
specific patients may reach high enough hepatic concentrations 
which lead to hepatocyte damage.
Our data suggest that the toxicity of dronedarone is mainly 
caused by the parent compound. In comparison to amiodarone, 
the N-dealkylated metabolites appear to play a less important 
role for the toxicity (Fig. 2D). The question concerning the tox-
icity of the N-dealkylated metabolites is clinically important, 
because, as we have shown in an in vitro study for amiodarone, 
CYP3A4 induction is a risk factor for hepatotoxicity, because 
the N-dealkylated metabolites are even more hepatotoxic than 
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FIG. 7. Effect on mitochondrial β-oxidation and intracellular fat accumulation. (A) Freshly isolated rat liver mitochondria were exposed to test compounds 
and acute inhibition of the rate of β-oxidation was determined. (B) HepG2 cells were exposed to test compounds for 24 h and β-oxidation was determined in 
permeabilized cells. (C) Intracellular triglyceride accumulation in HepG2 cells after drug exposure for 24 h. Drone: dronedarone, Amio: amiodarone. Data present 
the mean ± SEM. *p < 0.05 versus control. **p < 0.01 versus control.
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amiodarone (Waldhauser et al., 2006; Zahno et al., 2011). For 
dronedarone, this question can only be answered accurately, 
however, when toxicological studies can be carried out with the 
corresponding N-dealkylated metabolites.
The toxicity of dronedarone and amiodarone on the electron 
transport chain was quite similar. Both drugs inhibited complex 
I and uncoupled oxidative phosphorylation in isolated liver mito-
chondria in a concentration-dependent manner. Amiodarone 
inhibited also complex II, a finding observed for dronedarone 
only in HepG2 cells, but not in isolated rat liver mitochondria. 
For amiodarone, such findings have already been described in 
previous studies (Fromenty et al., 1990; Spaniol et al., 2001; 
Waldhauser et  al., 2006). For dronedarone, they are not sur-
prising, taking into account its structure with a benzofurane 
ring carrying a butyl side chain. These structural properties 
have been described in a previous study from our laboratory 
as being sufficient for mitochondrial toxicity (Kaufmann et al., 
2005). Importantly, the effects of both drugs on mitochondrial 
respiration were observed at lower concentrations than those 
required for cytotoxicity; taking into account the concentration 
dependency, it is likely that mitochondrial toxicity is a major 
reason for the cytotoxicity of these compounds. In contrast to 
our study, Serviddio et al. (2011) had not observed an inhibi-
tion of enzyme complexes of the electron transport chain in 
liver mitochondria isolated from rats treated with dronedar-
one. This discrepancy with our study may be explained by the 
observation that small molecules such as drugs can diffuse out 
of the mitochondria during the isolation procedure (Spaniol 
et al., 2003). In our experiments, we used either isolated mito-
chondria which were exposed to a known drug concentration 
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or permeabilized hepatocytes, in which the local environment 
of the mitochondria should not have changed much during the 
experimental procedures. Alternatively, the exposure in the 
study of Serviddio et al. (2011), may have been lower than in 
our in vitro investigations. In their study, Serviddio et al. used 
a dosage of ~40 mg dronedarone per kg body weight and they 
did not determine serum or tissue concentrations.
Besides affecting the electron transport chain, dronedar-
one and amiodarone also efficiently inhibited mitochondrial 
β-oxidation. Steatosis during the treatment with amiodarone 
is well established (Lewis et  al., 1990; Simon et  al., 1984) 
and may be a result from impaired β-oxidation (Fromenty and 
Pessayre, 1995; Kaufmann et al., 2005). A likely mechanism 
how amiodarone inhibits β-oxidation is by inhibiting carnitine 
palmitoyltransferase 1 (Kennedy et  al., 1996), which is con-
sidered to be rate limiting for β-oxidation. In contrast to ami-
odarone, the effects of dronedarone on the individual steps of 
β-oxidation are currently not known. The inhibition of mito-
chondrial β-oxidation has several consequences. As shown 
in the current and in previous investigations (Begriche et al., 
2011; Spaniol et  al., 2003), free fatty acids, acyl-CoAs, and 
triglycerides accumulate and may be toxic in hepatocytes. 
Accumulating free fatty acids have been described to uncouple 
oxidative phosphorylation, to increase ROS production, and to 
induce mitochondrial permeability transition, eventually lead-
ing to apoptosis (Rial et al., 2010).
Both inhibition of the electron transport chain (especially 
complexes I  and/or III) (Drose and Brandt, 2012; Liu et  al., 
2002) and inhibition of β-oxidation (Kaufmann et al., 2005) are 
associated with increased mitochondrial production of ROS. In 
the presence of inhibitors of complex I  or III, electrons may 
escape from the electron transport chain and react with molecu-
lar oxygen to form superoxide (Liu et al., 2002). Under normal 
conditions, superoxide is degraded by intramitochondrial anti-
oxidative systems such as glutathione peroxidase and super-
oxide dismutase (Bouitbir et  al., 2012; Troy and Shelanski, 
1994). The observed increase of the mRNA expression of 
mitochondrial SOD2 after treatment with 20µM dronedarone 
or 50µM amiodarone can therefore be regarded as a compen-
satory mechanism to counteract increased mitochondrial ROS 
production. The lacking increase of cytosolic SOD1 mRNA 
expression suggests that ROS production was primarily intram-
itochondrial. An increase of mitochondrial ROS production is 
a trigger for opening of the mitochondrial membrane perme-
ability transition pore, which is associated with cytochrome c 
release into the cytoplasm and induction of apoptosis and/or 
necrosis (Antico Arciuch et al., 2012). Mitochondrial release 
of cytochrome c and apoptosis could clearly be demonstrated 
in our study.
In conclusion, our investigations demonstrate that drone-
darone inhibits the electron transport chain and β-oxidation 
and uncouples oxidative phosphorylation of liver mitochon-
dria. Inhibition of complex I and of β-oxidation is associated 
with increased mitochondrial ROS production, which triggers 
mitochondrial membrane permeability transition and apopto-
sis. These findings may explain liver toxicity observed in pre-
disposed patients.
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